Px HealthCare

What Px HealthCare does

Px HealthCare Ltd., founded in 2012 by Dr. Anne Bruinvels and headquartered at the London Bioscience Innovation Centre, is a private UK digital health company (Company No. 09510306, wholly owned subsidiary of Px HealthCare Group Ltd.) that develops the OWise mobile and web application platform for cancer patients. Its two core products are OWise Breast Cancer (launched 2013 in the Netherlands and brought to the UK in 2016 via the NHS Innovation Accelerator) and OWise Prostate Cancer (launched March 2021 in the UK), both providing personalised medical information, tracking of 30+ symptoms and side effects, appointment and prescription management, personalised question lists for consultations, and secure audio recording of clinical consultations. The platform is built on encrypted cloud infrastructure with an anonymous data architecture in which personal identifiers are cryptographically hashed; OWise holds CE-mark as a Class I Medical Device and is the first oncology app used as a NICE Evidence Standards Framework case study exemplar, with the OWise breast cancer app listed in the NHS Apps Library and accredited by NHS Digital.

The technology stack consists of native iOS and Android applications (App Store IDs 558158100 and 1536593910), browser-based web applications (app.owise.net and pc.app.owise.net), and an EHR integration layer that has been deployed at NHS Lothian, allowing clinicians to view real-time patient-reported outcomes directly within the trust's electronic clinical record system. The business model is freemium at the patient layer (the app is provided entirely free to users with no in-app purchases, subscription, or premium tiers) with revenue generated indirectly via licensing of anonymised, aggregated treatment data to pharmaceutical, diagnostic, and academic research organisations. Critically, all anonymous treatment data is held by Stichting Px for Life, an independent ANBI foundation under Dutch law, and licensed back to Px HealthCare for operational use — a structural choice that protects the data asset from company distress and aligns the dataset with public-benefit research use.

The company operates with a small team of approximately 10 members, including co-founder Dr. David Bruinvels (Chief Medical Officer, MD/PhD Epidemiology, formerly at the Netherlands Cancer Institute), CTO Selwyn Kramer (founder of multiple IT companies with 15 years of mission-critical secure software development), Senior Data Scientist Shaun Gupta (PhD Particle Physics, Oxford; ex-IQVIA), and programme management staff. Cumulative disclosed funding is approximately £2.1M across multiple grant rounds (NESTA/Scottish Government, Innovate UK, EISMEA, FICHe) and one ~$1.75M round in 2019; additional grant income includes £60K from NESTA Healthier Lives Data Fund in 2020. Distribution combines a product-led consumer channel (App Store, Google Play, web app) with a B2B2C clinician-referral channel through NHS brochures and the Clinical Integration team, supplemented by partnerships with Look Good Feel Better, Future Dreams House, Breast Cancer Now, Macmillan, CoppaFeel, and Maggie's.

Name

Px HealthCare

Legal name

Px HealthCare Ltd.

Website

https://owise.uk

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Oncology Digital Health Software

NAICS

Offices of Physicians (62111)

SIC

Services-Health Services (8000)

akta.pro primary industry

Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

akta.pro secondary industries

Patient Engagement, Education & Messaging Platforms (portal/CRM integrated) (HLALABAJ), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Oncology patient support
• Digital health platform
• Symptom tracking software
• Cancer care apps
• Patient reported outcomes

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Free-to-End-User App: OWise is provided entirely free of charge to patients. The company does not charge individual users. The revenue model is not explicitly disclosed in the source materials. Based on the privacy policy, the company may generate revenue from anonymised, aggregated treatment data licensed to third-party medical research organisations (pharmaceutical companies, diagnostic companies, academic research centres). An independent foundation (Stichting Px for Life) holds the data rights, with data licensed back to the company for operation.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Px HealthCare develops and operates OWise, a CE-marked Class I medical device digital health platform delivered as mobile (iOS/Android) and web applications. OWise provides personalised cancer support to breast and prostate cancer patients through tailored medical information, symptom and side effect tracking (30+ items), appointment and prescription management, secure audio recording of consultations, and integration with NHS electronic health record systems for clinician access to real-time patient-reported outcomes.

Product overview

Px HealthCare offers OWise, a digital health platform consisting of two distinct mobile and web applications: OWise Breast Cancer (launched 2013 in the Netherlands, expanded to UK in 2016) and OWise Prostate Cancer (launched March 2021). Both apps provide personalised cancer patient support including symptom tracking, treatment information, appointment management, and secure communication with care teams. The platform also includes web application versions and printed patient brochures distributed through healthcare providers.

Differentiator

Problem solved

Functional benefit

Brands

• OWise Breast Cancer: Personalised cancer support app for breast cancer patients providing treatment information, appointment tracking, symptom monitoring, and doctor communication tools.
• OWise Prostate Cancer

Products and services

• OWise Breast Cancer App A clinically-validated mobile (iOS/Android) and web application providing personalised cancer support to breast cancer patients from diagnosis through treatment and recovery. Features include personalised medical information specific to diagnosis and treatment, appointment and prescription tracking, symptom and side effect monitoring (30+ items), diary entries, personalised question lists for consultations, and secure data sharing with care teams. CE-marked as a Class I Medical Device and listed in the NHS Apps Library.
• OWise Prostate Cancer App A co-designed mobile (iOS/Android) and web application providing personalised support to prostate cancer patients. Helps patients track prostate-cancer-specific side effects and symptoms (e.g., urinary incontinence, fatigue, sexual function), access personalised prostate cancer information, manage treatment plans, and generate tailored questions for clinical consultations.
• OWise Web Application Browser-based versions of the OWise breast and prostate cancer apps providing the same functionality as the mobile applications (personalised information, symptom tracking, appointment management, secure consultation recording) without requiring a download. Used as a fallback for Android 12+ users.
• OWise Patient Brochures Free printed and digital brochures used by NHS care teams to onboard patients to OWise. Includes space for clinical nurse specialists or consultants to fill in diagnostic and treatment details, enabling patients to start using OWise with personalised content tied to their specific care plan.

Quantifiable outcome

• In a randomised controlled trial at Memorial Sloan Kettering Cancer Center, patients using electronic PRO symptom monitoring had improved HRQL (34% improved vs 18% with usual care), fewer ER admissions (34% vs 41%), fewer hospitalisations, and longer chemotherapy duration (8.2 vs 6.3 months). 75% 1-year survival vs 69% with usual care.
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• NHS England / UCLPartners (NHS Innovation Accelerator)coreStrategic or Co-development Partner · 1 January 2016OWise breast cancer was selected for the NHS Innovation Accelerator Programme in 2016, which facilitated its introduction and adoption within the UK NHS. This partnership provided the primary pathway into the UK healthcare market and conferred significant institutional credibility.
• NHS LothiancoreStrategic or Co-development PartnerOWise has been successfully integrated into NHS Lothian's cancer centres and electronic health record system in Scotland. Clinicians can access real-time patient-reported symptom data directly within their clinical workflow. This integration represents OWise's most advanced hospital-level deployment and serves as a flagship reference site.
• Royal Marsden NHS Foundation TrustcoreStrategic or Co-development PartnerThe Royal Marsden is conducting the ADAPT randomised controlled clinical trial evaluating OWise for supporting breast cancer patients during treatment (Lidington et al., 2020; BMC). This trial provides clinical validation and peer-reviewed evidence for OWise's efficacy.
• NICE (National Institute for Health and Care Excellence)coreStrategic or Co-development PartnerOWise was the first oncology app used as a case study example in the NICE Evidence Standards Framework for Digital Health Technologies. NICE endorsement provides OWise with significant regulatory credibility and is referenced prominently in the company's marketing.
• NHS Digital / NHS Apps LibrarycoreStrategic or Co-development PartnerOWise is listed in the NHS Apps Library and accredited by NHS Digital, indicating it has passed NHS digital security and clinical safety standards. This is the primary trust signal for UK patients and clinicians.
• Stichting Px for LifecoreStrategic or Co-development PartnerStichting Px for Life is an independent non-profit ANBI foundation established under Dutch law to manage and protect the anonymous treatment data collected by OWise. All anonymous treatment data is automatically assigned to the foundation and licensed back to Px HealthCare. This structure ensures that user data would not become company assets in financial difficulties and must be used for public benefit medical research.
• Look Good Feel BetterminorGTM or Marketing PartnerOWise partnered with Look Good Feel Better charity for a blog article discussing appearance changes during cancer treatment. LGFB offers confidence-boosting workshops for women, young adults, and men undergoing cancer treatment. OWise referenced the partnership to highlight complementary support resources for patients concerned about body image.
• Future Dreams HouseminorGTM or Marketing PartnerOWise references Future Dreams House — a London-based charity offering in-person workshops and community support for breast cancer patients — as a recommended support resource. The charity is mentioned in OWise blog content as part of the support ecosystem for patients during and after treatment.
• CoppaFeelminorGTM or Marketing PartnerOWise blog features CoppaFeel — a breast cancer awareness charity — as a recommended resource. OWise also references CoppaFeel's trekking events and awareness campaigns as part of the patient community ecosystem.
• Breast Cancer NowminorGTM or Marketing PartnerOWise blog references Breast Cancer Now's 'Someone Like Me' initiative and body image resources. Breast Cancer Now is cited as a support organisation for newly diagnosed patients and is referenced in patient blog content.
• Macmillan Cancer SupportminorGTM or Marketing PartnerOWise references Macmillan Cancer Support as a major support charity offering practical and emotional assistance to cancer patients, including financial guidance and support services.
• Siemens Healthineers / Economist Intelligence UnitminorGTM or Marketing PartnerOWise was featured in an Economist Intelligence Unit analysis commissioned by Siemens Healthineers exploring how digital health apps are transforming cancer care. The feature was published as 'The future of healthcare is through apps' and provided third-party validation of OWise's value in hospital settings.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Carevive Systems: Oncology care management and patient-reported outcomes platform used by cancer centers to capture symptoms, coordinate care plans, and generate real-world evidence. Directly comparable to OWise in collecting PROs for cancer patients and surfacing clinician-relevant insights across multiple oncology indications.
• HealthLoop (GetWellNetwork): Patient engagement platform supporting automated check-ins, symptom monitoring, and care plan adherence across multiple specialties including oncology. Comparable to OWise in providing automated patient-reported outcome capture and care team notifications, though with broader multi-specialty coverage.
• Kaiku Health: Oncology digital therapeutics platform for symptom monitoring and patient-reported outcomes, acquired by Elekta in 2021. Directly comparable to OWise in offering cancer-specific PRO tracking, symptom monitoring, and clinician dashboards across multiple cancer types, but with broader indication coverage and integration into Elekta's radiation oncology systems.
• Voluntis (Aptar Pharma): Digital therapeutics company developing software-based oncology symptom management applications. Directly comparable to OWise in providing CE-marked oncology digital therapeutics for PRO monitoring, drug adherence, and clinician communication across cancer treatment regimens.
• Noona Healthcare: Oncology patient engagement platform providing PRO capture, symptom management, and care team communication, also owned by Elekta. Directly competes with OWise in enabling cancer patients to report symptoms and supporting care teams between visits, with similar free-to-patient and hospital-licensing business model.
• Navigating Cancer: Patient engagement platform for oncology practices offering symptom tracking, care plan management, and patient communication tools. Comparable to OWise in targeting oncology care teams with patient-facing tools that capture PROs and integrate into clinic workflows.

Broad incumbents

• Epic Systems (MyChart): Dominant US hospital EHR vendor whose MyChart patient portal provides symptom capture, appointment management, and secure messaging. Competes with OWise as the incumbent patient engagement layer already embedded in many hospital EHR installations, constraining standalone digital health platforms from displacing MyChart in oncology workflows.
• Varian Medical Systems (Siemens Healthineers): Major oncology treatment and software vendor (now part of Siemens Healthineers) offering oncology information systems, treatment planning, and patient engagement capabilities. Comparable to OWise as a broader oncology software portfolio that competes for hospital IT budget and EHR integration slots.
• Elekta: Global leader in radiation oncology and radiosurgery that acquired both Kaiku Health and Noona Healthcare. Competes with OWise at the broader oncology solutions level, where Elekta can bundle PRO symptom monitoring into its installed base of linear accelerators and oncology information systems.

Emerging players

• Caresense: Digital health platform supporting remote patient monitoring and symptom tracking for oncology and chronic conditions. Comparable to OWise as a smaller, emerging oncology-focused patient monitoring and engagement company pursuing similar hospital integration and clinical validation pathways.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PxHealthCare
• YouTubeyoutube.com/PxHealthCare
• Facebookfacebook.com/owiseapp
• LinkedInlinkedin.com/company/px-healthcare
• Instagraminstagram.com/owisebreast

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Px HealthCare